Five Prime Therapeutics, Inc.

Incyte Corporation

Bristol-myers Squibb Compnay

Ernestine A Lee

Kevin Hestir

Elizabeth Bosch

Lewis T Williams

Diane Hollenbaugh

Minmin Qin

Ali Sadra

Stephen Kohl Doberstein

Ge Wu

Henry Yue

Mariah R Baughn

Justin Wong

April J A Hafalia

Ameena R Gandhi

Monique G Yao

Yan Lu

Hongbing Zhang

Danniel B Nguyen

Vicki S Elliott

Rajagopal Gururajan

Justin G P Wong

Craig H Ison

Anita Swarnakar

Michael B Thornton

Wen Luo

Reena Khare

Thomas W Richardson

Joseph P Marquis

Shanya D Becha

Soo Yeun Lee

Uyen K Tran

Ian J Forsythe

Pei Jin

Narinder K Chawla-Walia

Joana X Li

Amy D Wilson

Shannon Marshall

Haishan Lin

Cindy Leo

Aileen Zhou

Dirk Behrens

Robert Forgan Halenbeck

Min Mei Huang

Thomas Linnemann

Keting Chu

Amy L Tsui Collins

Preeti G Lal

Janice K Au-Young

Y Tom Tang

Brian Wong

Katherine E Lewis

Thomas Brennan

Dyung Aina M Lu

David Bellovin

Emma Masteller

Chandra S Arvizu

Neil Burford

Julie Hambleton

Angelo M Delegeane

Robert Sikorski

Roopa M Reddy

Li Ding

Bridget A Warren

Junming Yang

Narinder K Chawla

Steven J Smith

Janine Powers

Brendan M Duggan

Catherine M Tribouley

Jayalaxmi Ramkumar

Farrah A Khan

Penny E Phillips

Debopriya Das

Liam Kearney

Michael Carleton

Stephen Todd

Deborah A Kallick

Mark L Borowsky

Roberto Hernandez

Serena Kimi Perna

Ke Xu

Dimple Pandya

Justin G Wong

Steven Doberstein

Steven Smith

Thomas Five Prime Therapeutics Inc Linnemann

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Antibodies to human &#x3b2;-adrenergic receptor kinase

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

FGFR2-IIIb fusion proteins and methods of making them

Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.

FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same

Human &#x3b2;-adrenergic receptor kinase polypeptide and methods

ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Antibodies to stromal cell-derived factor-1 polypeptides

FGFR3-IIIc fusion proteins

Various embodiments of the invention provide human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Human &#x3b2;-adrenergic receptor kinase nucleic acid molecule

Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

Growing community of inventors

Kensington, CA, United States of America

Ernestine A Lee